Mechanistic basis of an epistatic interaction reducing age at onset in hereditary spastic paraplegia

The mechanisms underlying disease modifier gene effects are rarely understood. Newton et al. report that deletion of DPY30 reduces age at onset in hereditary spastic paraplegia caused by SPAST mutations. They demonstrate that both genes regulate cellular pathways that pathologically impact lysosome...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brain (London, England : 1878) England : 1878), 2018-05, Vol.141 (5), p.1286-1299
Hauptverfasser: Newton, Timothy, Allison, Rachel, Edgar, James R, Lumb, Jennifer H, Rodger, Catherine E, Manna, Paul T, Rizo, Tania, Kohl, Zacharias, Nygren, Anders O H, Arning, Larissa, Schüle, Rebecca, Depienne, Christel, Goldberg, Lisa, Frahm, Christiane, Stevanin, Giovanni, Durr, Alexandra, Schöls, Ludger, Winner, Beate, Beetz, Christian, Reid, Evan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The mechanisms underlying disease modifier gene effects are rarely understood. Newton et al. report that deletion of DPY30 reduces age at onset in hereditary spastic paraplegia caused by SPAST mutations. They demonstrate that both genes regulate cellular pathways that pathologically impact lysosome function, providing a mechanistic explanation for this interaction. Abstract Many genetic neurological disorders exhibit variable expression within affected families, often exemplified by variations in disease age at onset. Epistatic effects (i.e. effects of modifier genes on the disease gene) may underlie this variation, but the mechanistic basis for such epistatic interactions is rarely understood. Here we report a novel epistatic interaction between SPAST and the contiguous gene DPY30, which modifies age at onset in hereditary spastic paraplegia, a genetic axonopathy. We found that patients with hereditary spastic paraplegia caused by genomic deletions of SPAST that extended into DPY30 had a significantly younger age at onset. We show that, like spastin, the protein encoded by SPAST, the DPY30 protein controls endosomal tubule fission, traffic of mannose 6-phosphate receptors from endosomes to the Golgi, and lysosomal ultrastructural morphology. We propose that additive effects on this pathway explain the reduced age at onset of hereditary spastic paraplegia in patients who are haploinsufficient for both genes.
ISSN:0006-8950
1460-2156
DOI:10.1093/brain/awy034